Case Studies

FDA Surveillance Audit Closed With Zero Observations

By August 20, 2026September 11th, 2026No Comments
Scientist working with cell and gene therapy equipment

A CGT client was managing five programs submitted under the biologics framework, with quality systems and documentation that hadn’t kept pace. We overhauled the quality management system, updated regulatory documentation, and redesigned facilities for compliance and scale.

Impact for the client:

  • Zero FDA observations during surveillance audit
  • Facility redesign completed for compliance and scalability
  • Full QMS remediation and IND updates delivered
Skip to content